Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
- Status
- COMPLETED
- Phase
- PHASE3
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
- Status
- COMPLETED
- Phase
- N/A
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
- Status
- COMPLETED
- Phase
- PHASE3